(Total Views: 123)
Posted On: 09/26/2024 4:08:43 PM
Post# of 175
NetworkNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) for all antiviral drug developments from TheraCour. According to the announcement, the MoU encompasses all antiviral drug developments and is a crucial step that provides NanoViricides with certain intellectual property rights for developing treatments against any viral infections.
The announcement noted that the MoU enables NanoViricides to quickly and easily discover an increasing number of antiviral indications of NV-387, its lead broad-spectrum drug, and add them to its portfolio of drugs in its development pipeline. In addition, the agreement expands the company’s ability to opportunistically and rapidly develop certain “Trojan Horse” nanoviricide drugs to treat viral infections of public importance. The MoU also codifies how NanoViricides and TheraCour negotiate licenses to specific antiviral fields.
NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at http://nnw.fm/NNVC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) for all antiviral drug developments from TheraCour. According to the announcement, the MoU encompasses all antiviral drug developments and is a crucial step that provides NanoViricides with certain intellectual property rights for developing treatments against any viral infections.
The announcement noted that the MoU enables NanoViricides to quickly and easily discover an increasing number of antiviral indications of NV-387, its lead broad-spectrum drug, and add them to its portfolio of drugs in its development pipeline. In addition, the agreement expands the company’s ability to opportunistically and rapidly develop certain “Trojan Horse” nanoviricide drugs to treat viral infections of public importance. The MoU also codifies how NanoViricides and TheraCour negotiate licenses to specific antiviral fields.
NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at http://nnw.fm/NNVC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
